News Focus
News Focus
Replies to #36424 on Biotech Values
icon url

quantumdot

10/28/06 10:39 PM

#36436 RE: DewDiligence #36424

Re: Tyzeka vs. Hespera

These data make me want to see a 4th arm; that is Telbivudine switching to Adefovir.

Just looking at the tail ends of the curves makes me think that the sprinter would be better followed by the marathoner than vice-versa.